We think Lenz is well positioned to capture COVID opportunity for several reasons, Kelly Shi, PhD, equity analyst with Jefferies, and three colleagues wrote Monday in a research note. 1) Vaccination is still not available to children <16 years old; 2) ~25% of US population declines to get vacc
